Getting Through To Autism: Seaside Pioneers New Drugs
This article was originally published in Start Up
Tiny Seaside Therapeutics is doing pioneering work to develop disease-modifying drugs for Autism Spectrum Disorders, a group of syndromes that not long ago was thought immutable and even blamed on bad parenting. By targeting molecular pathways associated with the single gene disorder fragile X syndrome, Seaside hopes to extrapolate its work to other “autisms” and help people most affected by those disorders learn to walk, talk, or even live independent lives.
You may also be interested in...
Pfizer has thoroughly revamped its approach to neuroscience R&D, emphasizing disease biology and neural circuitry, moving its research team from Groton, Conn. to Cambridge, Mass., and hiring an eminent neuroscientist to lead the group.
With a last round of applications due Oct. 8, the Neurotherapeutics Network is hoping for increased industry participation in a portfolio of 20 projects in the hit-to-lead-optimization stage that will have access to CROs under contract to NIH. Projects that continue to meet milestones will be supported through proof-of-concept in humans.
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials